trial · primary record
Atezolizumab
Extensive Stage Lung Small Cell Carcinoma
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 138 |
| Primary completion | 2027-04-30 |
| Primary endpoint | Progression-free survival (PFS) (Phase II) |
| Registry ID | NCT04402788 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:28.669Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04402788
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- ATEZOLIZUMAB · approval
- Atezolizumab · compound